Skip to main content
Premium Trial:

Request an Annual Quote

How Many and For How Long?

Researchers are hoping to develop a blood test to gauge whether SARS-CoV-2 vaccines are effective as well as how long their protection may last, NPR reports. It adds that such a test may be needed if new or updated vaccines are necessary to combat viral variants.

According to NPR, researchers at the University of Oxford are exposing people who previously had COVID-19 to the virus to learn what level of antibodies are needed to fight off infection. Knowing that cut-off titer could help determine how long vaccine-induced protection lasts, it says.

At the same time, researchers at Fred Hutchinson Cancer Research Center are analyzing blood samples from people taken the day they received the Moderna vaccine as well as the day they received their second dose and a few weeks after that. This analysis, too, could give insight into antibody levels needed to prevent infection, particularly if any of the 1,600 people in the study later develop COVID-19.

"Everyone in the field is waiting for those results to give more confidence in being able to approve other vaccines more quickly and more reliably. So, we're getting close. We're almost there, actually," the Fred Hutch's Peter Gilbert says.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.